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Aims High-sensitivity cardiac troponin I (cTnI) assays hold promise in detecting the transition fromhypertrophy to heart failure
in aortic stenosis. We sought to investigate the mechanism for troponin release in patients with aortic stenosis and
whether plasma cTnI concentrations are associated with long-term outcome.
Methods
and results
Plasma cTnI concentrations were measured in two patient cohorts using a high-sensitivity assay. First, in the Mechanism
Cohort, 122 patients with aortic stenosis (median age 71, 67%male, aortic valve area 1.0+ 0.4 cm2) underwent cardio-
vascularmagnetic resonance and echocardiography to assess left ventricular (LV)myocardialmass, function, and fibrosis.
The indexed LV mass and measures of replacement fibrosis (late gadolinium enhancement) were associated with cTnI
concentrations independent of age, sex, coronary artery disease, aortic stenosis severity, and diastolic function. In the
separate Outcome Cohort, 131 patients originally recruited into the Scottish Aortic Stenosis and Lipid Lowering
Trial, Impact of REgression (SALTIRE) study, had long-term follow-up for the occurrence of aortic valve replacement
(AVR) and cardiovascular deaths. Over a median follow-up of 10.6 years (1178 patient-years), 24 patients died from a
cardiovascularcause and60patientshadanAVR. PlasmacTnI concentrationswereassociatedwithAVRorcardiovascular
death HR 1.77 (95% CI, 1.22 to 2.55) independent of age, sex, systolic ejection fraction, and aortic stenosis severity.
Conclusions In patients with aortic stenosis, plasma cTnI concentration is associated with advanced hypertrophy and replacement
myocardial fibrosis as well as AVR or cardiovascular death.
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Introduction
Aortic stenosis is the commonest formof valvular heart disease in the
western world, and its prevalence is expected to double in the next
two decades.1 Current guidelines advocate aortic valve replacement
(AVR) in patients with symptoms and severe valve narrowing.2,3
However, there is apoorcorrelationbetweenthe severityof stenosis
and symptom onset making the management of asymptomatic
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patients controversial.2 This apparent discrepancy might in part
be explained by heterogeneity in the hypertrophic response to
aortic stenosis, which itself is an independent marker of an adverse
prognosis.4–6
Hypertrophy occurs in response to the increased afterload
imposed by aortic valve narrowing on the left ventricle. Initially this
restores wall stress and maintains cardiac performance, but decom-
pensation ultimately ensues and patients develop symptoms, adverse
events, and the need for surgery. The transition from hypertrophy
to heart failure is characterized by progressive cardiomyocyte
death and replacement fibrosis.7 Myocardial fibrosis can be detected
using twocardiovascularmagnetic resonance (CMR) techniques: late
gadolinium enhancement (replacement fibrosis) and T1 mapping
(diffuse interstitial fibrosis) with data indicating that the former pro-
vides useful prognostic information.5,8 However, to date, a marker of
myocyte cell death has been lacking.
Cardiac troponin is a structural protein present in cardiac muscle,
with plasma troponin concentrations considered a highly specific
marker for myocardial injury.9 Recent advances in assay technology
have greatly improved sensitivity, now allowing quantification of
troponin with a high degree of precision at extremely low plasma
concentrations.10
In this study, we hypothesized that detection of myocardial injury
by high-sensitivity troponin assays may provide an early indicator of
left ventricular (LV) decompensation and be associated with future
adverse events in patients with aortic stenosis.
Methods
Two cohorts of stable patients with aortic stenosis were recruited from
cardiology outpatient clinics across three centres in Southeast Scotland.
First, we determined the association between plasma cardiac troponin I
(cTnI) concentrations and LV functional and structural abnormalities on
cardiacmagnetic resonance (MechanismCohort), and second,weexam-
ined the prognostic role of plasma cTnI concentrations in patients with
aortic stenosis (Outcome Cohort). The study was conducted in accord-
ancewith theDeclaration of Helsinki and approved by the local research
ethics committee. Written informed consent was obtained from all
participants.
Patient populations
Mechanism Cohort
Patientswithmild to severe aortic stenosiswere recruited prospectively.
We excluded patients who had other significant (moderate or severe)
valvular heart disease or cardiomyopathies (acquired or inherited).
Presence of coronary artery disease was defined by previous infarction,
clinical symptoms of angina (in those with mild or moderate aortic sten-
osis), evidence of myocardial ischaemia, or .50% luminal stenosis in
a major epicardial vessel. In addition, thirteen age- and sex-matched
healthy volunteers without clinically significant heart disease were
recruited from the local community.
Outcome Cohort
The Outcome Cohort comprised patients recruited into the Scottish
Aortic Stenosis and Lipid Lowering Trial, Impact of REgression
(SALTIRE) study. The study design and inclusion and exclusion criteria
have been described previously.11 In brief, from March 2001 to April
2002, 155patientswith asymptomaticmoderate to severe aortic stenosis
were randomly assigned to receive either atorvastatin 80 mg or placebo
once daily. Patients were excluded if they were already on a statin, if AVR
was planned, or if they had moderate or severe LV systolic impairment.
Only patients with plasma samples available for cTnI analysis were
included in the present analysis.
Blood sampling and analysis
In theMechanismCohort, brain natriuretic peptide (BNP) concentration
was analysed with the Triage BNP assay (Biosite, Inc., San Diego, CA,
USA). The inter-assay coefficient of variation was 10% at 28.8 pg/mL,
with a detection range of 5–1300 pg/mL.12 In the Outcome Cohort,
N-terminal proBNP (NT-proBNP) concentration was measured using
the Elecysys 2010 analyzer (Roche Diagnostics Ltd, Lewes, UK). This
assay has ,0.001% cross-reactivity with bioactive BNP, and the inter-
assay coefficients of variation range from 0.9 to 5.5%.13
Plasma cTnI concentrations were determined by the ARCHITECT
STAT high-sensitivity cTnI assay (Abbott Laboratories, Abbott Park, Il,
USA) in both cohorts. The lower limit of detection of this assay is
1.2 ng/L;10 the 99th percentile from a healthy reference population is
26 ng/L.14 Our inter-assay coefficient of variation is 10% at 6 ng/L
(see Supplementary material online).
Echocardiography
All participants underwent a comprehensive echocardiographic assess-
ment to determine the severity of aortic stenosis. Peak aortic jet velocity
and mean pressure gradient were measured by velocity time integral
spectral Doppler, and the aortic valve area derived using the continuity
equation. The severity of aortic stenosis was assessed and classified
according to the European Association of Echocardiography/American
Societyof Echocardiology guidelines.15Trans-mitral early (E) and late dia-
stolic velocities and deceleration time of early filling velocity were mea-
sured at the tips of the mitral valve leaflets using pulse-wave Doppler.
Early (e′) diastolic velocities of the medial and lateral mitral annulus
were measured using pulse-wave tissue Doppler imaging. Diastolic func-
tion was determined using the E/e′ ratio.
Cardiovascular magnetic resonance
in the Mechanism Cohort
Cardiovascular magnetic resonance was performed using a 3T scanner
(MAGNETOM Verio, Siemens AG, Healthcare Sector, Erlangen,
Germany). Short-axis cine images were obtained using a balanced
steady-state free precession sequence from the mitral valve annulus to
the apex (8-mm parallel slices with 2 mm spacing) for the assessment
of LV function and volumes. LV volumes, mass, and ejection fraction
were assessed using dedicated software (Argus Ventricular Function,
Siemens AG Healthcare Sector, Erlangen, Germany), and values were
indexed to body surface area.
Focal myocardial fibrosis was assessed using the late gadolinium
enhancement (LGE) technique, performed 10–15 min following
0.1 mmol/kg of gadobutrol (Gadovist, Bayer Pharma AG, Germany).
Two approacheswere used: an inversion-recovery fast gradient echo se-
quence and a phase-sensitive inversion-recovery sequence (performed
in two phase-encoding directions for the exclusion of artefact). The
inversion time was optimized to achieve satisfactory nulling of the myo-
cardium. Assessment for the presence of mid-wall LGE was determined
visually and independently by two experienced operators. The extent of
mid-wall LGE was quantified with QMASS software (Medis Medical
Imaging Systems, Leiden, theNetherlands) using a signal intensity thresh-
oldof.2standarddeviationsabove themeanvalue inan adjacentnormal
region of myocardium. Areas of inversion artefact, or contamination by
blood pool or epicardial fat, were excluded.
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Myocardial T1 mapping was performed to investigate diffuse
myocardial fibrosis using the Modified Look-Locker Inversion-recovery
sequence (flip angle 358; minimum TI 100 ms; TI increment of 80 ms;
time delay of 150 ms with a heartbeat acquisition scheme of 3–3–5).16
We have previously described a standardized approach for the analysis
of myocardial extracellular volume fraction (ECV) in patients with
aortic stenosis, demonstrating that it offers improved reproducibility
(+3%) and the ability to identify disease states compared with other
T1 mapping techniques.17 In brief, regions of interest were drawn
around the myocardium on short-axis pre-contrast motion-corrected
myocardial T1 maps and then applied to corresponding 20-min post-
contrast maps with minor adjustments made to avoid partial volume
effects and artefact (OsiriXversion4.1.1,Geneva, Switzerland). Extracel-
lular volume fraction values were calculated according to: ECV ¼
[DR1myocardium/DR1blood2pool] × [1-haematocrit], where DR1 ¼ (1/
post-contrast T1-1/pre-contrast T1). Haematocrit was determined at
the time of CMR.
Computed tomography in the Outcome
Cohort
Computed tomography calcium scoring of the coronary arteries and
aortic valve was performed on ECG-gated non-contrast scans using a
double helix scanner (Twin II Flash, Philips Medical Systems). All images
were analysed by a single operator using the Picker Cardiac Scoring soft-
ware as previously described.11
Follow-up in the Outcome Cohort
Clinical outcomes were obtained and adjudicated by two independent
investigators blinded to plasma cTnI and BNP concentrations. All
in-hospital and community deaths were captured in a comprehensive
national database: the General Register of Scotland. Cardiovascular
death was based on the cause of death stated on the death certificate.
We defined cardiovascular death as death due to myocardial infarction,
sudden cardiac death, heart failure, stroke, death due to cardiovascular
procedures, and death due to other cardiovascular causes. Each death
was classified as cardiac or non-cardiac by two independent investigators
and anydiscrepancy resolvedbyconsensus.All eventswereconfirmedby
independent reviewof eachpatient’s electronic healthcare recordwhere
available. Surgical AVR (no patients underwent transcatheter aortic valve
implantation in the follow-up period) was determined from individual
patient medical records. All patients in the Outcome Cohort were
managed in the tertiary cardiac centre, where patients are reviewed at
a multi-disciplinary meeting prior to undergoing cardiac surgery. Only
patients with established indications were referred for AVR according
to the European Society of Cardiology recommendations.2,18
Statistical analysis
Baseline characteristics are reported as percentages for categorical
variables, mean+ standard deviation or median [interquartile range],
as appropriate. We used one-way analysis-of-variance to compare con-
tinuous parametric data and the Kruskall–Wallis test for non-parametric
data. Chi-square tests were used for categorical baseline characteristics.
Analyses were performed in R version 2.15.2 (Vienna, Austria) and SPSS
Version 20.0.0 (Armonk,NY,USA: IBMCorp). Statistical significancewas
taken as a two-sided P, 0.05.
Mechanism Cohort
We assessed the association of plasma cTnI concentrations with mea-
sures of aortic stenosis and ventricular remodelling using univariate and
multivariable linear regression models. Plasma cTnI concentrations
were log-transformed as this variable was highly skewed.
Outcome Cohort
Kaplan–Meier analysis was performed across tertiles of cTnI concentra-
tions. To accommodate competing risks, the associationbetween time to
AVR or cardiovascular deaths and plasma cTnI concentrations (log-
transformed [base 2])wasmodelled as a composite endpoint inCoxpro-
portional hazard models.
Furthermore, we examined whether relative change in cTnI concen-
trations at 1 year (cTnI at 1 year—baseline cTnI, both log-transformed)
was associated with increased odds of an event at 3-year and 5-year
follow-up independent of baseline cTnI concentrations (results in Sup-
plementary material online).
Results
We recruited 122 patients into the Mechanism Cohort (71 [65–77]
years, 67% males, aortic valve area 1.0+ 0.4 cm2) and analysed 131
patients in the Outcome Cohort (69 [62–75] years, 70% males,
aortic valve area 1.1+0.4 cm2) (Tables 1 and 2). Thirteen healthy
volunteers were recruited, who were well matched in terms of age
(65 [57–75] years) and sex (62% male) compared with the other
groups and did not have any history of diabetes mellitus, hyperten-
sion, or coronary artery disease.
Plasma cTnI concentrations above the lower limit of detection of
1.2 ng/L were present in 98% of our patients with aortic stenosis
and increased in both cohorts comparedwith the healthy volunteers
(MechanismCohort6.6 [3.8–12.0] ng/L;OutcomeCohort7.6 [5.7–
13.2] ng/L; healthy volunteers 3.2 [1.3–11.0] ng/L). The distribution
of plasma cardiac troponin I concentrations was skewed in a similar
pattern across the two cohorts (see Supplementary material
online). There were 10 patients (8.1%) in the Mechanism Cohort
and 10 patients (7.6%) in the Outcome Cohort with plasma cTnI
concentrations of .26 ng/L (the 99th percentile derived from the
healthy reference population). There was no difference in renal
function across tertiles of cTnI in patients with aortic stenosis.
Mechanism for increased cardiac
troponin I concentrations
In the Mechanism Cohort, patients with aortic stenosis had an
increased LV mass index compared with healthy controls, although
there was no difference in LV volumes or ejection fraction
(Table 1). Furthermore, these patients had higher ECV values
(27.7+2.5 vs. 25.9+ 1.6%, P ¼ 0.01), and 35 patients (28%) had a
mid-wall pattern of LGE: an observation not seen among the
healthy volunteers (Figure 1).
Plasma cTnI concentrations correlated with LV mass index, inde-
pendent of coronary artery disease status (r ¼ 0.50, P, 0.001;
Figure 2). A weaker correlation was also observed between
plasma cTnI concentrations and peak aortic jet velocity (r ¼ 0.32,
P, 0.001). Furthermore, patients with aortic stenosis and mid-wall
LGEhada two-fold increase inplasmacTnI concentrations compared
with those without (9.5 [5.7, 20.3] ng/L vs. 4.3 [3.3, 7.9] ng/L,
P ¼ 0.02; Figure 3).
With univariate analysis, age, mean pressure gradient, mean e′, the
LVmass index, andmeasures of both diffuse and replacement fibrosis
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were all associated with plasma cTnI concentrations (Table 3; all
P, 0.05). However, only age, LV mass index, and %LGE were inde-
pendently associated with plasma cTnI concentrations (Model 1;
Table 3).
Interestingly, there was no difference in plasma cTnI concentra-
tions between patients with and without coronary artery disease
(6.9 [4.0, 13.5] ng/L vs. 6.2 [3.5, 10.0] ng/L, P ¼ 0.28). This was sup-
ported by data from the Outcome Cohort where no correlation
was observed between the coronary calcium scores and plasma
cTnI concentrations (r ¼ 20.03, P ¼ 0.71).
Prognostic value of cardiac troponin I
concentrations
Patients in the OutcomeCohort were stratified by tertiles of plasma
cTnI concentration (Table 2). In comparison with the lowest tertile,
patients in the highest tertile were older (70+9 vs. 64+12 years,
P ¼ 0.03) and had an increased ventricular mass (393+ 100 vs.
327+111 g, P ¼ 0.02). However, there were no differences in co-
morbidity, severity of aortic stenosis, or coronary calcium scores
across the tertiles (P. 0.1 for all; Table 2).
Over a median of 10.6 years of follow-up (1178 patient-years), 60
patients had anAVR, 24 died fromacardiovascular cause, and 47 died
fromnon-cardiovascular causes. Ten-yearevent-free survival rate for
AVRor cardiovascular deaths differed across the tertiles of cTnI con-
centrations (log rank test for trend, P ¼ 0.016, Figure 4). Plasma cTnI
concentration was associated with an increased risk of AVR or
cardiovascular deaths in unadjusted analysis (HR 1.65 per two-fold
increment in cTnI concentration; 95% CI, 1.15–2.38, P ¼ 0.007)
with minimal attenuation in the effect estimate after adjusting for
age, sex, and ejection fraction (Table 4). Moreover, this association
persisted after further adjustment for severity of aortic stenosis
(HR 1.77; 95% CI, 1.22–2.35, P ¼ 0.002) as well as the coronary
artery and aortic valve calcium scores (HR 2.10; 95% CI, 1.22–
3.61, P ¼ 0.007).
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Table 1 Baseline characteristics of patients with aortic stenosis in the Mechanism Cohort
Healthy volunteers (n5 13) Mechanism Cohort (n5 122) P-value
Clinical characteristics
Age, years 65 [57, 75] 71 [65, 77] 0.13
Male sex, n (%) 8 (62) 82 (67) 0.76
Diabetes mellitus, n (%) 0 14 (11) –
Hypertension, n (%) 0 78 (63) –
CAD, n (%) 0 41 (33) –
SBP, mmHg 148+12 149+20 0.35
NYHA class, n (%)
I 13 (100) 63 (52) –
II 0 35 (28)
III 0 24 (20)
Creatinine, mmol/L 69+8 78+17 0.06
Cardiac troponin I concentration, ng/L 3.2 [1.3, 11.0] 6.6 [3.8, 12.0] 0.03
BNP, pg/mL 10.3 [5.6, 18.1] 26.4 [10.6, 53.9] 0.009
Echocardiography
Vm, m/s 1.4+0.2 3.7+0.9 ,0.001
MPG, mmHg 4+1 32+18 ,0.001
AVA, cm2 2.4+0.7 1.0+0.4 ,0.001
Valvulo-arterial impedance, mmHg/mL/m2 4.5+1.1 4.5+1.2 0.96
Mean e′, cm/s 8.1+2.7 6.2+1.9 0.001
Mean E/e′ 7.9+2.2 14.8+8.1 0.003
Cardiac MRI
Indexed EDV, mL/m2 73+13 72+14 0.71
Indexed ESV, mL/m2 27+7 24+9 0.28
Indexed SV, mL/m2 46+7 48+9 0.68
Ejection fraction, % 64+3 67+7 0.12
Indexed LVM, g/m2 70+14 89+22 0.004
LVM/EDV, g/mL 0.96+0.13 1.26+0.28 ,0.001
ECV, % 25.9+1.6 27.7+2.5 0.01
CAD, coronary artery disease; SBP, systolic blood pressure; BNP, brain natriuretic peptide; Vm, peak aortic jet velocity; MPG, mean pressure gradient; AVA, aortic valve area;
EDV, end diastolic volume; ESV, end systolic volume; LVM, left ventricular mass; ECV, extracellular volume fraction; %LGE, amount of late gadolinium enhancement.
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Mechanism and prognosis associated
with BNP concentrations
Serum BNP concentrations were higher in patients with aortic sten-
osis compared with healthy volunteers (26.4 [10.6,53.9] vs. 10.3
[5.6,18.1] ng/mL, P ¼ 0.009; Table 1). In patients with aortic stenosis,
BNP concentrations increased with age, disease severity, diastolic
dysfunction, LV mass index myocardial fibrosis, the presence of cor-
onary artery disease, and symptoms (all P, 0.05; see Supplementary
material online).However, onmultivariable analysis, only agewas sig-
nificantly associated with BNP concentrations (P, 0.001; see Sup-
plementary material online).
In the Outcome Cohort, NT-proBNP was not associated with
AVR or cardiovascular deaths in both unadjusted (HR 1.15 per
two-fold increment in NT-proBNP concentration; 95% CI, 0.86–
1.53, P ¼ 0.34) and adjusted analyses (see Supplementary material
online). Importantly, NT-proBNP concentration did not modify the
association between troponin and time to AVR or cardiovascular
deaths (HR 1.60; 95% CI 1.10–2.34, P ¼ 0.01).
Discussion
This is the first dataset to explore mechanisms and outcomes asso-
ciated with cTnI concentrations using a high-sensitivity assay in
patients with aortic stenosis. In more than 250 patients with aortic
stenosis, we have demonstrated that levels are detectable in 98%
of subjects and increased compared with age- and sex-matched
healthy volunteers. Plasma cTnI concentrations were not associated
with the presence of co-existent coronary artery disease or the
severity of valve narrowing on multivariable analysis. Instead,
plasma cTnI concentrations demonstrated a close association with
themagnitude of LV hypertrophy and the presence of mid-wall myo-
cardial fibrosis.Moreover, high-sensitivity plasmacTnI concentration
showed an independent association with long-term risk of AVR or
cardiovascular deaths. We therefore believe that high-sensitivity
plasma cTnI concentrations hold potential as an objective marker
of LV decompensation in patientswith aortic stenosis and as a poten-
tial early trigger to AVR.
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Table 2 Characteristics of patients in the Outcome Cohort by tertiles of troponin I concentrations
All patients Tertile 1
(≤6.3 ng/L)
Tertile 2
(6.4–10.6 ng/L)
Tertile 3
(≥10.7 ng/L)
P-value
(n 5 131) (n5 42) (n 5 45) (n 5 44)
Clinical characteristics
Age, years 67+10 64+12 69+10 70+9 0.03
Male sex, n (%) 91 (70) 24 (57) 32 (71) 35 (79) 0.08
Diabetes Mellitus, n (%) 4 (3) 1 (2) 1 (2) 2 (5) –
Hypertension, n (%) 66 (50) 18 (43) 22 (49) 26 (59) 0.31
CAD, n (%) 22 (16) 6 (14) 7 (16) 9 (21) 0.72
SBP, mmHg 145+20 139+17 148+21 146+19 0.07
NYHA class, n (%)
I 117 (89) 38 (90) 41 (91) 38 (86) 0.53
II 14 (11) 4 (10) 4 (9) 6 (14)
Creatinine, mmol/L 91+21 86+17 92+20 95+25 0.12
NT-pro-BNP, pg/mL 198.0 [113.5, 530.5] 129.5 [76.3, 228.0] 180.0 [89.0, 416.0] 507.0 [181.5, 1103.0] 0.008
Echocardiography
Vm, m/s 3.4+0.7 3.4+0.6 3.4+0.6 3.5+0.7 0.45
MPG, mmHg 26+11 25+10 25+10 28+13 0.35
AVA, cm2 1.1+0.4 1.0+0.4 1.1+0.4 1.0+0.4 0.72
Indexed AVA, cm2/m2 0.5+0.2 0.5+0.2 0.6+0.2 0.5+0.2 0.66
LVM, g 357+107 327+111 350+102 393+100 0.02
Indexed LVM, g/m2 180+50 165+54 172+49 196+49 0.06
Fractional shortening, % 40+8 42+9 42+8 37+6 0.004
Ejection fraction, % 70+10 72+11 72+9 66+8 0.007
LVH, n (%) 109 (95) 34 (81) 36 (80) 39 (89) 0.49
Impaired LVEF,50%, n (%) 4 (3) 1 (2) 2 (4) 2 (5) 0.84
Computed tomography
Coronary calcium score, log AU 1.6+1.3 1.5+1.3 1.5+1.3 1.8+1.1 0.53
Aortic valve calcium score, log AU 3.6+0.6 3.6+0.5 3.6+0.5 3.7+0.8 0.61
CAD, coronary artery disease; SBP, systolic blood pressure; BNP, brain natriuretic peptide; Vm, peak aortic jet velocity; MPG,mean pressure gradient; AVA, aortic valve area; EDV, end
diastolic volume; ESV, end systolic volume; LVM, left ventricularmass; LVH, left ventricular hypertrophy, basedonASE/EAE sex-specific criteria; LVEF, left ventricular ejection fraction.
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Aortic stenosis is defined not only by the development of progres-
sive valve narrowing but also by the LV hypertrophic response that
ensues. Whilst this initially restores wall stress, decompensation
due to progressive cell death and fibrosis ultimately occurs and
patients transition from hypertrophy to heart failure.4 Because of
the associated adverse prognosis, current guidelines recommend
surgery in patients with severe stenosis and evidence of such decom-
pensation, detected either on the basis of symptom development or
anejection fractionof,50%.Unfortunately, symptomsareoften fre-
quently difficult to assess whereas an ejection fraction of ,50%
Figure 1 Comparison of two patients with severe aortic stenosis. Both had similar severity of aortic valve narrowing (peak aortic jet velocity in
Patient A was 4.8 m/s and Patient B 5.1 m/s) and neither had significant coronary artery disease. However, the high-sensitivity troponin I concen-
trationwasmore than four-fold higher in Patient A (11.9 ng/L) comparedwith Patient B (2.5 ng/L), consistentwith themore advanced hypertrophic
response observed in this patient (left ventricular mass index in Patient A was 114 g/m2 and Patient B was 81 g/m2). Furthermore, Patient A had
evidence of focal mid-wall fibrosis on late gadolinium imaging (LGE) and myocardial T1 mapping (Patient B did not) and more extensive collagen
staining with picrosirius red staining on myocardial biopsy.
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occurs late in the disease process and is often irreversible. There is
therefore emerging interest in developing novel, objective biomar-
kers of decompensation for patients with aortic stenosis. Data
from our study suggests that troponin has the potential to be such
a marker.
Todate elevated cardiac troponinhasbeenconsidered the sine qua
non for the diagnosis of myocardial infarction.19 However, marked
improvements in assay sensitivity now allow quantification of
plasma cTnI concentrations in the majority of the healthy popula-
tion.10 In our study, cTnI was detectable in 98% of patients with
aortic stenosis andexceeded the recommendeddiagnostic threshold
for myocardial infarction in 7.9%. Patients with stable coronary
disease have been reported to have higher plasma troponin concen-
trations, with elevated levels being associatedwith long-term cardio-
vascular risk.20 However in our cohort of patients with aortic
stenosis, there were no differences in plasma troponin concentra-
tions between those with and without coronary artery disease.
Instead plasma troponin concentrations were independently asso-
ciated with an advanced hypertrophic response and replacement
myocardial fibrosis. Indeed, the latter occurred over and above the
effects of LV mass, supporting our hypothesis that cTnI release
relates to themyocardial injury that accompanies ventricular decom-
pensation and myocardial fibrosis.
The poor prognosis associated with increased troponin concen-
trations offers further support for this model. At 10 years, more
than a half of patients in the highest tertile of plasma cTnI had under-
gone an AVR or died from cardiovascular disease. Moreover, plasma
cTnI concentrations were associated with AVR or cardiovascular
deaths, independent of the burden of coronary atherosclerosis
(as assessed using coronary calcium scoring) as well as age, sex,
Figure 2 Correlation between indexed left ventricular mass and plasma cardiac troponin I concentrations (log-transformed). Similar correlation
was seen in patients with (A) and without (B) coronary artery disease.
Figure 3 Patients with aortic stenosis and mid-wall late gadolin-
iumenhancement (LGE)had a two-fold increase in cardiac troponin
I concentrations compared with those without LGE and age- and
sex-matched healthy patients.
Chin et al.2318
systolic ejection fraction, echocardiographic measures of aortic
stenosis severity, and the aortic valve calcium score.
A recent study demonstrated an association between high-
sensitivity cardiac troponin T concentrations and echocardiographic
measures of LV modelling in aortic stenosis.21 Our data confirm and
extend these findings using CMR, which has allowed us to investigate
the remodelling response in greater detail and crucially assess the re-
lationship with myocardial fibrosis, thereby providing additional
mechanistic data.We therefore believe that the plasma cTnI concen-
tration measured by a high-sensitivity assay has considerable poten-
tial as an early biomarker of LV decompensation and as a powerful
prognostic tool in patients with aortic stenosis. Moreover, this test
is inexpensive and easy to perform making any future transition into
routine clinical practice readily achievable. However, considerable
overlap was observed between patients with aortic stenosis and
ourcontrol cohort.This is perhapsunsurprising, givencTnI is released
as a consequence of awide range ofmyocardial insults. A future strat-
egy where asymptomatic aortic stenosis patients with elevated or
increasing plasma troponin concentrations subsequently proceed
to CMR for confirmation of myocardial fibrosis and LV
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Table 3 Univariate and multivariable linear regression analysis to examine association of variables with plasma cardiac
troponin I concentrations
Variables Univariate Multivariable—Model 1
(included %LGE)
Multivariable—Model 2
(included ECV)
Relative change in
troponin I concentration
(95% CI)
P-value Relative change in
troponin I concentration
(95% CI)
P-value Relative change in
troponin I concentration
(95% CI)
P-value
Age, per 10 years 1.32 (1.07–1.44) 0.004 1.49 (1.14–1.80) 0.002 1.36 (1.09–1.72) 0.006
Male sex 1.31 (0.90–1.92) 0.16 0.79 (0.44–1.42) 0.44 0.80 (0.46–1.39) 0.42
Diabetes mellitus 0.92 (0.52–1.61) 0.76
Hypertension 1.21 (0.83–1.74) 0.33
CAD 1.20 (0.82–1.75) 0.35 1.01 (0.58–1.73) 0.96 1.17 (0.72–1.91) 0.53
MPG, per 10mmHg 1.17 (1.02–1.35) 0.02 0.92 (0.79–1.06) 0.27 0.93 (0.73–1.06) 0.28
Mean e′, cm/s 0.86 (0.78–0.95) 0.002 1.08 (0.93–1.27) 0.30 1.02 (0.88–1.19) 0.78
Indexed LVM,
per 10 g/m2
1.23 (1.15–1.32) ,0.001 1.34 (1.15–1.55) ,0.001 1.41 (1.23–1.62) ,0.001
%LGE, % 1.13 (1.08–1.17) ,0.001 1.11 (1.03–1.19) 0.006
ECV, % 1.15 (1.07–1.23) ,0.001 1.11 (1.00–1.21) 0.05
See Table 1 for abbreviations.
Figure4 Ten-year event-free survival for composite endpoint of
aortic valve replacement or cardiovascular death by tertiles of
cardiac troponin I concentrations. Patients in the highest tertile
were associated with lower survival rates compared with patients
in the other tertiles (log rank test for trend, P ¼ 0.016).
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Table 4 Hazard ratios predicting time to valve
replacement or cardiovascular death for troponin I
concentrations in adjusted and unadjusted analyses
Model Hazard ratio (95% CI) P-value
Model 1 1.65 (1.15–2.38) 0.007
Model 2 1.61 (1.11–2.35) 0.01
Model 3 1.63 (1.11–2.38) 0.01
Model 4 1.77 (1.22–2.55) 0.002
Model 5 2.10 (1.22–3.61) 0.007
Model 1—unadjusted; Model 2—adjusting for age and sex; Model 3—as model 2
additionally adjusting for systolic ejection fraction;Model 4—asmodel 2 additionally
adjusting formean pressure gradient;Model 5—asmodel 2 additionally adjusting for
coronary and aortic valve calcium score.
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decompensation is therefore attractive. Large-scale prospective
studies are now required to investigate the use of these two biomar-
kers in the management and risk stratification of patients with aortic
stenosis and whether the above approach might identify asymptom-
atic patients who would benefit from early surgery.
In contrast to troponin, BNP did not have prognostic value in our
study. BNP is an endogenous cardiac hormone released in response
to increasing LV wall stress and most commonly used in the assess-
ment of patients with heart failure. It is therefore only likely to be
released late in the transition from hypertrophy to heart failure,
making it of limited value in detecting signs of early decompensation
in asymptomatic patients. Given that this is the group in whom novel
biomarkers of LV decompensation are most likely to be useful, we
believe that troponin holds greater clinical promise than BNP.
Limitations
CMRwas not available at the inception of the SALTIRE study. There-
fore, we needed to recruit another patient population to investigate
the mechanism for troponin release in aortic stenosis. However,
plasma cTnI concentrations in the Outcome Cohort also displayed
a close association with LV mass determined by echocardiography
and were unrelated to the burden of coronary atherosclerosis or
the severity of valvular stenosis. Similarmechanismswould therefore
seem to govern cTnI release across both groups. Another limitation
is the lack of more sensitive markers of LV systolic dysfunction in
the Mechanism Cohort, for example CMR tagging techniques.
However, we elected not to perform these due to concerns about
lengthening the scanning protocol in this elderly cohort of patients
and compromising the detection of myocardial fibrosis. Finally, data
on short-term biological variability (the change in concentration
from one occasion to another) are very limited in disease states.
However, we do not anticipate significant short-term variability in
chronic conditions such as aortic stenosis, although this will require
further validation.
Conclusions
In patients with aortic stenosis, plasma cTnI concentrations are a
marker of LV decompensation and myocardial fibrosis that are asso-
ciatedwith cardiovascular deaths and AVR. High-sensitivity troponin
assays hold major promise as a future clinical tool for patients with
this condition.
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